The 15th anniversary of the EHA congress

Bookmark and Share
Published: 3 Aug 2010
Views: 6391
Rating:
Save
Prof Robin Foà, Sapienza University of Rome, Italy
Prof Robin Foà talks about the increasing importance of the annual EHA congress, not just within Europe but across the world. The 2010 Barcelona congress is the first to hold a joint symposium with the Japanese Society of Hematology. Prof Foà explains how this, in addition to the collaborative work with the American Society of Hematology, helps to share knowledge and raise awareness of problems being faced in different parts of the world.

Related Videos

The advances in the management of patients with Hodgkin lymphoma and non-Hodgkin...
Dr Eduardo Sotomayor - H. Lee Moffitt Cancer Center & Research Institute, Florid...
The advances in the management of patients with Hodgkin lymphoma and non-Hodgkin lymphoma ( Dr Eduardo Sotomayor - H. Lee Moffitt Cancer Center & Research Institute, Florida, USA )
9 Jul 2022
Axicabtagene ciloleucel provides superior EFS vs standard of care in elderly wit...
Dr Anna Sureda - Blood Cell Barcelona Hematology Institute, Barcelona, Spain
Axicabtagene ciloleucel provides superior EFS vs standard of care in elderly with relapsed/refractory large B-cell lymphoma ( Dr Anna Sureda - Blood Cell Barcelona Hematology Institute, Barcelona, Spain )
1 Jul 2022
Ibrutinib plus venetoclax for 1-L treatment of CLL and small lymphocytic lymphom...
Dr Carol Moreno - University of Barcelona, Barcelona, Spain
Ibrutinib plus venetoclax for 1-L treatment of CLL and small lymphocytic lymphoma shows a clinically meaningful PFS ( Dr Carol Moreno - University of Barcelona, Barcelona, Spain )
21 Jun 2022
CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed...
Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Spain
CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma ( Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Spain )
14 Jun 2022
A bispecific antibody talquetamab shows promising efficacy in relapsed/refractor...
Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands
A bispecific antibody talquetamab shows promising efficacy in relapsed/refractory multiple myeloma ( Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands )
13 Jun 2022
Ponatinib and blinatumomab shows complete molecular response for patients with P...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
Ponatinib and blinatumomab shows complete molecular response for patients with Philadelphia chromosome-positive ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )
13 Jun 2022
Subcutaneous isatuximab administration in combination with pomalidomide-dexameth...
Prof Hang Quach - St.Vincent’s Hospital, Sydney, Australia
Subcutaneous isatuximab administration in combination with pomalidomide-dexamethasone in RRMM can improve convenience and relieve burden for patients ( Prof Hang Quach - St.Vincent’s Hospital, Sydney, Australia )
13 Jun 2022
Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in ...
Prof Barbara Eichhorst - The University of Cologne, Cologne, Germany
Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in frontline CLL ( Prof Barbara Eichhorst - The University of Cologne, Cologne, Germany )
13 Jun 2022
A novel CAR-T cell therapy targeting BCMA is highly effective for patients with ...
Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Barcelona, Spain
A novel CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma ( Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Barcelona, Spain )
13 Jun 2022